AC Immune 2nd Milestone Payment in Phase 2b Trial in Preclinical Alzheimer’s

 

• Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September
• Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD
• FDA Fast Track designation granted in July for ACI-35.030 (now “JNJ-2056”) for AD
  
  

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.

https://www.globenewswire.com/news-release/2024/09/17/2947287/0/en/AC-Immune-Receives-Second-Milestone-Payment-Following-Progress-in-Phase-2b-ReTain-Trial-of-ACI-35-030-in-Preclinical-Alzheimer-s-Disease.html